De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Supernus Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Supernus Pharmaceuticals is gedaald met een gemiddeld jaarlijks percentage van -35.8%, terwijl de winst van de Pharmaceuticals -industrie jaarlijks daalde met 0.3%. De inkomsten zijn groeide met een gemiddeld percentage van 9.7% per jaar. Het rendement op het eigen vermogen Supernus Pharmaceuticals bedraagt 0.5% en de nettomarge bedraagt 0.8%.

Belangrijke informatie

-35.8%

Groei van de winst

-36.3%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie	6.0%
Inkomstengroei	9.7%
Rendement op eigen vermogen	0.5%
Nettomarge	0.8%
Laatste winstupdate	30 Jun 2024

Recente prestatie-updates uit het verleden

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19

Recent updates

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Sep 12

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Aug 19

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

Jul 02

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Apr 24

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Oct 19

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Oct 10

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio

Aug 19

Supernus Pharmaceuticals' (NASDAQ:SUPN) Soft Earnings Are Actually Better Than They Appear

Aug 16

Supernus: A Work In Progress

Jul 29

Supernus: New Beginnings

Mar 28

Brokers Are Upgrading Their Views On Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) With These New Forecasts

Dec 02

Is Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Trading At A 34% Discount?

Nov 30

Is Supernus Pharmaceuticals (NASDAQ:SUPN) Using Too Much Debt?

Oct 19

Opbrengsten en kosten

Hoe Supernus Pharmaceuticals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGM:SUPN Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Jun 24	630	5	336	97
31 Mar 24	597	-16	337	95
31 Dec 23	608	1	336	92
30 Sep 23	611	26	329	86
30 Jun 23	634	43	359	83
31 Mar 23	668	52	372	75
31 Dec 22	667	61	377	75
30 Sep 22	659	38	405	78
30 Jun 22	630	57	365	78
31 Mar 22	601	73	334	77
31 Dec 21	580	53	305	90
30 Sep 21	564	82	251	87
30 Jun 21	571	100	234	85
31 Mar 21	556	111	212	91
31 Dec 20	520	127	201	76
30 Sep 20	477	129	177	78
30 Jun 20	424	118	162	78
31 Mar 20	402	116	152	73
31 Dec 19	393	113	153	69
30 Sep 19	408	106	161	65
30 Jun 19	409	105	162	69
31 Mar 19	404	103	164	72
31 Dec 18	409	111	155	89
30 Sep 18	381	99	152	76
30 Jun 18	359	87	152	68
31 Mar 18	335	73	147	59
31 Dec 17	302	57	138	50
30 Sep 17	276	58	133	47
30 Jun 17	253	104	118	42
31 Mar 17	228	97	109	42
31 Dec 16	215	91	106	43
30 Sep 16	196	84	101	39
30 Jun 16	179	26	98	40
31 Mar 16	163	18	95	36
31 Dec 15	147	14	89	29
30 Sep 15	135	11	84	25
30 Jun 15	118	5	78	21
31 Mar 15	112	5	74	19
31 Dec 14	93	-11	73	20
30 Sep 14	72	-37	70	19
30 Jun 14	50	-59	67	18
31 Mar 14	21	-89	60	17
31 Dec 13	12	-92	56	17

Kwaliteitswinsten: SUPN heeft een grote eenmalige verlies van $14.1M wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.

Groeiende winstmarge: De huidige netto winstmarges (0.8%) SUPN } zijn lager dan vorig jaar (6.8%).

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: De winst van SUPN is de afgelopen 5 jaar met 35.8% per jaar gedaald.

Versnelling van de groei: De winstgroei SUPN is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.

Winst versus industrie: SUPN had het afgelopen jaar een negatieve winstgroei ( -87.9% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Pharmaceuticals ( 13% ).

Rendement op eigen vermogen

Hoge ROE: Het Rendement op eigen vermogen ( 0.5% ) van SUPN wordt als laag beschouwd.

Supernus Pharmaceuticals Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

First quarter 2024 earnings released: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Recent updates

Supernus: Stock Slides As Qelbree Sales Questioned, But Positives Still Outweigh Negatives

Supernus Pharmaceuticals' (NASDAQ:SUPN) Conservative Accounting Might Explain Soft Earnings

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Supernus Pharmaceuticals, Inc. Raises Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Supernus Pharmaceuticals: So-So Neuroscience Portfolio, With ADHD Standout

First quarter 2024 earnings released: EPS: US$0.002 (vs US$0.31 in 1Q 2023)

Supernus Pharmaceuticals, Inc. Reiterates Financial Guidance for the Full Year 2024

Supernus Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Supernus Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 08, 2024

Subdued Growth No Barrier To Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Price

Consensus EPS estimates fall from profit to US$0.01 loss

Insider notifies of intention to sell stock

Consensus EPS estimates increase by 44%, revenue downgraded

Supernus Pharmaceuticals: Moving Through An 'Inflection Year'

Founder exercised options and sold US$469k worth of stock

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Insider notifies of intention to sell stock

Consensus EPS estimates upgraded to US$0.06 loss

Founder exercised options and sold US$331k worth of stock

Consensus estimates of losses per share improve by 58%

Investor sentiment improves as stock rises 18%

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Supernus Pharmaceuticals, Inc. Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Insider selling

Consensus EPS estimates fall by 64%

Supernus Pharmaceuticals, Inc. Resubmits NDA for SPN-830 Apomorphine Infusion Device

Supernus Pharmaceuticals, Inc. Announces New Qelbree®? Data Showing Improvement in ADHD Symptoms

Founder exercised options and sold US$539k worth of stock

Insider notifies of intention to sell stock

Supernus Pharmaceuticals, Inc. Appoints Bethany L. Sensenig to Board of Directors

Consensus EPS estimates fall by 40%

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Supernus Pharmaceuticals, Inc. Reiterates Earnings Guidance for the Full Year 2023

Supernus Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Supernus Pharmaceuticals, Inc.(NasdaqGM:SUPN) dropped from Russell 2000 Value-Defensive Index

Consensus estimates of losses per share improve by 84%

Founder exercised options and sold US$547k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Year 2023

We Think Supernus Pharmaceuticals (NASDAQ:SUPN) Can Stay On Top Of Its Debt

Senior Vice President of Quality recently sold US$172k worth of stock

Consensus EPS estimates fall from profit to US$0.033 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

Supernus Pharmaceuticals, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Founder exercised options and sold US$446k worth of stock

Does Supernus Pharmaceuticals (NASDAQ:SUPN) Have A Healthy Balance Sheet?

Insider exercised options and sold US$149k worth of stock

Insider notifies of intention to sell stock

Independent Chairman of the Board exercised options to buy US$311k worth of stock.

Founder exercised options and sold US$439k worth of stock

Consensus forecasts updated

Founder exercised options and sold US$343k worth of stock

Insufficient new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Supernus Pharmaceuticals, Inc. Revises Earnings Guidance for the Full Year 2022

Supernus Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 08, 2022

These 4 Measures Indicate That Supernus Pharmaceuticals (NASDAQ:SUPN) Is Using Debt Reasonably Well

Price target decreased to US$35.33

Supernus Pharmaceuticals, Inc. Provides Regulatory Update on SPN-830

Supernus stock falls 12.6% after FDA declines to approve Parkinson’s disease treatment

Supernus Pharmaceuticals: Deep Expertise In CNS, Eyes On Qelbree Launch And Parkinson Portfolio